European Cardiac Biomarker Market

European Cardiac Biomarker Market Size, Share & Trends Analysis Report by Type (Creatine kinase (CK-MB), Troponins(T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others), By Application (Myocardial infraction, Congestive Heart Failure, Acute coronary syndrome, Atherosclerosis, and Others), By Location of Testing(Laboratory testing and Point of care testing) and Forecast 2019-2025
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2020118 | Category : Biotechnology | Delivery Format: /

The European cardiac biomarker market is estimated to grow significantly at a CAGR of around 7.1% during the forecast period. The cardiac biomarker market has a significant scope in the European region due to growing heart related diseases such as CVD, CHD, and stroke.  Europe has the highest rates for CVD, CHD and other heart diseases which create a huge demand for diagnosis of cardiac diseases. Europe has a quality healthcare system and adopts the latest cardiology devices and technology to treat heart patients. Europe has a huge economic burden of heart related disease such as CVD, CHD, stroke and other heart diseases. Cardiac biomarkers can be used in the quick diagnosis of cardiac disease. Therefore, the rising incidence of CVD is expected to increase the demand for a cardiac biomarker in the region, which would prevail in the market.

The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the European cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on Application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.  

The companies which are contributing to the growth of the European cardiac biomarker market include Abbott Laboratories, BioMérieux S.A., Cisbio Bioassays SAS, Danaher Corp., F. Hoffmann-La Roche AG, HyTest Ltd, Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the European cardiac biomarker market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  1.  European Cardiac biomarker Market Research and Analysis by Type
  2.  European Cardiac biomarker Market Research and Analysis by Application
  3.  European Cardiac biomarker Market Research and Analysis by Location of Testing 

The Report Covers

  • Comprehensive research methodology of the European cardiac biomarker market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European cardiac biomarker market.
  • Insights about market determinants which are stimulating the European cardiac biomarker market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis 

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants 

4.1. Motivators

4.2. Restraints

4.3. Opportunities 

5. Market Segmentation

5.1. European Cardiac Biomarker Market by Type 

5.1.1. Creatine kinase (CK-MB)

5.1.2. Troponins(T,I)

5.1.3. Myoglobin

5.1.4. Natriuretic peptides (BNP & NT-PROBNP)

5.1.5. Ischemia modified albumin

5.1.6. Others

5.2. European Cardiac Biomarker Market by Application

5.2.1. Myocardial infraction

5.2.2. Congestive heart failure

5.2.3. Acute coronary syndrome

5.2.4. Atherosclerosis

5.2.5. Others

5.3. European Cardiac Biomarker Market by Location of Testing

5.3.1. Laboratory testing

5.3.2. Point of care testing

6. Regional Analysis

6.1. UK

6.2. Germany

6.3. France 

6.4. Italy 

6.5. Spain

6.6. Rest of Europe

7. Company Profiles

7.1. Abbott Laboratories 

7.2. BioMérieux S.A. 

7.3. Cisbio Bioassays SAS 

7.4. Danaher Corp.

7.5. F. Hoffmann-La Roche AG

7.6. HyTest Ltd 

7.7. Merck KGaA

7.8. Randox Laboratories Ltd. 

7.9. Siemens Healthcare GmbH 

7.10.  Thermo Fisher Scientific Inc.


1. EUROPEAN CARDIAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

2. EUROPEAN CARDIAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION) 

3. EUROPEAN CARDIAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)

4. EUROPEAN CARDIAC BIOMARKER MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2018-2025 ($ MILLION)


1. EUROPEAN CARDIAC BIOMARKER MARKET SHARE BY COUNTRY, 2018 VS 2025 (%)

2. EUROPEAN CARDIAC BIOMARKER MARKET SHARE BY TYPE, 2018 VS 2025 (%)

3. EUROPEAN CARDIAC BIOMARKER MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)

4. EUROPEAN CARDIAC BIOMARKER MARKET SHARE BY LOCATION OF TESTING, 2018 VS 2025 (%)

5. UK CARDIAC BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)

6. GERMANY CARDIAC BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)

7. FRANCE CARDIAC BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)

8. ITALY CARDIAC BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)

9. SPAIN CARDIAC BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)

10. REST OF EUROPE CARDIAC BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)